Afuco™ Anti-Human CTGF ADCC Recombinant Antibody (FG-3019), ADCC Enhanced (CAT#: AFC-184CL)

Anti-CTGF ADCC Enhanced Antibody (FG-3019) is an ADCC enhanced antibody produced by our Afuco™ platform. FG-3019 is an investigational therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. The clinical studies of FG-3019 in idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis show that, it has been well tolerated, with no apparent safety signals, in more than ten clinical studies and more than 340 treated patients to date.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 The FG-3019 binding epitope overlaps with the VWC domain of connective tissue growth factor (CTGF).

Figure 1 The FG-3019 binding epitope overlaps with the VWC domain of connective tissue growth factor (CTGF).

(A) The region of the FG-3019 binding epitope (CTGF amino acids 142 to 157, indicated in yellow) is superimposed on the structure of the collagen IIa VWC domain. By sequence homology, the general structural features of this domain are predicted to be conserved in CTGF and other CCN (connective tissue growth factor) proteins. The predicted FG-3019 binding site lies outside of a fibronectin-1-like module within the VWC domain of CTGF. A physical interaction between the VWC domain of Xenopus CTGF and TGF-β family members TGF-β1 and bone morphogenetic protein (BMP)-4 was reported. The location of the VWC domain relative to the insulin-like growth factor binding protein (IGF-BP), thrombospondin-1 (TSP1) and C-terminal cysteine knot (CT) homology domains of CCN family members is also indicated. (B) Recombinant human CTGF, CYR61 and NOV proteins (visualized by Coomassie blue in the upper panel) were analyzed by western blot using FG-3019, anti-CYR61 and anti-NOV antibodies. FG-3019 specifically bound CTGF without crossreacting with CYR61 or NOV.

Wang, Q.,Usinger,W.,Nichols,B.,Gray,J.,Xu,L.,Seeley,T.W., & Lin, A. (2011).Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease. Fibrogenesis & tissue repair, 4(1), 4.

Figure 2 Hepatic and renal fibrosis in mice receiving transforming growth factor (TGF)-β and connective tissue growth factor (CTGF) is ameliorated by FG-3019 treatment.

Figure 2 Hepatic and renal fibrosis in mice receiving transforming growth factor (TGF)-β and connective tissue growth factor (CTGF) is ameliorated by FG-3019 treatment.

(A, B) Liver and (C, D) kidney of 21-day-old animals coadministered TGF-β2 and CTGF; animals were treated with either (A, C) vehicle or (B, D) FG-3019. All agents were administered daily for 20 days beginning one day after birth. Arrows indicate regions of robust capsular fibrosis inhibited by FG-3019 treatment. Representative images are shown (all haematoxylin and eosin, original magnification × 200).

Wang, Q.,Usinger,W.,Nichols,B.,Gray,J.,Xu,L.,Seeley,T.W., & Lin, A. (2011).Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease. Fibrogenesis & tissue repair, 4(1), 4.

Figure 3 FG-3019 inhibits renal collagen deposition after unilateral ureteral obstruction (UUO).

Figure 3 FG-3019 inhibits renal collagen deposition after unilateral ureteral obstruction (UUO).

Hydroxyproline:proline (Hyp:Pro) ratios in renal tissues from UUO mice are expressed as the mean change above the mean Hyp:Pro ratio of unligated control kidneys (0.0446 ± 0.0005, n = 35). Mean renal Hyp:Pro ratio increases for the 10 and 30 mg/kg FG-3019 treatment groups (gray bars) were 20% and 15% lower than for the UUO kidneys of vehicle-treated controls (white bar), respectively. *P < 0.05 compared with UUO + vehicle (analysis of variance, Fisher's least significant difference).

Wang, Q.,Usinger,W.,Nichols,B.,Gray,J.,Xu,L.,Seeley,T.W., & Lin, A. (2011).Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease. Fibrogenesis & tissue repair, 4(1), 4.

Figure 4 FG-3019 inhibits collagen deposition in lungs of bleomycin-treated mice.

Figure 4 FG-3019 inhibits collagen deposition in lungs of bleomycin-treated mice.

Pulmonary hydroxyproline (Hyp) content (μg/lung) of bleomycin-treated mice is expressed as the mean change from Hyp content of healthy control lungs (285 ± 8 μg/lung, mean ± SEM, n = 10). Mean Hyp content (μg/lung) increases for the 3, 10 and 30 mg/kg FG-3019 treatment groups (gray bars) were 27, 38 and 13% lower than for the bleomycin mice treated with vehicle (white bar), respectively. *P = 0.056 vs. bleomycin + vehicle (ANOVA, Fisher's LSD).

Wang, Q.,Usinger,W.,Nichols,B.,Gray,J.,Xu,L.,Seeley,T.W., & Lin, A. (2011).Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease. Fibrogenesis & tissue repair, 4(1), 4.

Figure 5 CTGF is essential for persistent fibrosis.

Figure 5 CTGF is essential for persistent fibrosis.

One day old neonatal mice were injected SC daily for 7 days with 800 ng TGFβ2 alone or with 400 ng CTGF. FG-3019 was also administered to one group that received CTGF. The injections were then stopped for 4 days and the mice were sacrificed to examine the deposition of ECM components and cellular invasion. Panel A: the experimental design. Panel B: A cross section of the skin, SC space and underlying muscle from representative mice is shown. The arrows point out fibrotic response to the various treatments.

Finger,E.C.,Cheng, C.F.,Williams,T.R.,Rankin,E.B.,Bedogni,B.,Tachiki,L.,& Powell,M.B.(2014).CTGF is a therapeutic target for metastatic melanoma.Oncogene,33(9),1093.


Specifications

  • Host Species
  • Human
  • Derivation
  • Human
  • Type
  • ADCC enhanced antibody
  • Species Reactivity
  • Human
  • Related Disease
  • Idiopathic pulmonary fibrosis

Product Property

  • Purity
  • >95% as judged by SDS-polyacrylamide gel electrophoresis
  • Storage
  • Store at -20°C. Open under aseptic conditions.

Target

  • Alternative Names
  • CTGF; connective tissue growth factor; CCN2; NOV2; HCS24; IGFBP8; IBP-8; IGFBP-8; CCN family member 2; IGF-binding protein 8; hypertrophic chondrocyte-specific protein 24; insulin-like growth factor-binding protein 8

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "CTGF"

Recombinant Antibody

Fc Glycosylation

CAT Product Name Application Type
Gly-119LC Recombinant Anti-Human CTGF Antibody (Fc glycosylation) ELISA Human antibody

scFv Fragment Antibody

CAT Product Name Application Type
HPAB-0181-YC-S(P) Human Anti-CTGF Recombinant Antibody; scFv Fragment (HPAB-0181-YC-S(P)) ELISA, FuncS Human scFv

Fab Fragment Antibody

CAT Product Name Application Type
HPAB-0181-YC-F(E) Human Anti-CTGF Recombinant Antibody; Fab Fragment (HPAB-0181-YC-F(E)) ELISA, FuncS Human Fab

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-443CQ Afuco™ Anti-CTGF ADCC Recombinant Antibody (Pamrevlumab), ADCC Enhanced ELISA, IHC, FC, IP, IF, Inhib ADCC enhanced antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for AFC-184CL. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare